Sotagliflozin Shows Stronger Anti-Clotting Effect Than Empagliflozin
A Journal of Clinical Investigation study found the diabetes and heart drug reduced blood clot formation in mice more than a related medication did.
Updated on Nov. 1, 2026 in Diabetes
Live Poll
Would you trust a new drug that prevents blood clots if it raised bleeding risk?
Researchers at Michigan Medicine and the University of Michigan Medical School reported in the Journal of Clinical Investigation on October 14, 2026, that sotagliflozin reduced clot formation in mice with injured blood vessels by approximately 60%, compared with 5% to 10% for empagliflozin.
Why it matters
The findings suggest sotagliflozin's broader action on glucose transport proteins may contribute to cardiovascular protection beyond what empagliflozin provides, which researchers had sought to explain. For Michigan residents and the wider US population affected by type 2 diabetes, the results point to a possible new explanation for how these drugs protect the heart.
The mouse study showed approximately 60% reduction in clot formation for sotagliflozin versus 5% to 10% for empagliflozin, and genetic removal of SGLT1 from platelets cut clotting by about 40%. Whether endothelial cells contribute to these effects and whether the platelet effect prevents cardiovascular events in humans remain unknown.
The players
Michigan Medicine
The academic medical center of the University of Michigan, where the researchers conducted the study.
University of Michigan Medical School
The medical school whose co-senior authors led the research on sotagliflozin's effects on blood clotting.
The details
Scientists compared sotagliflozin and empagliflozin using blood samples from healthy volunteers and people with type 2 diabetes, finding sotagliflozin significantly reduced platelet activation while empagliflozin had little comparable effect. Sotagliflozin acts on both SGLT2 and SGLT1, while empagliflozin primarily blocks SGLT2, and neither genetic SGLT1 removal nor mizagliflozin fully reproduced sotagliflozin's results.
Timeline
October 14, 2026: Journal of Clinical Investigation published the sotagliflozin platelet study.
Health Landscape
The study builds on FDA-approved cardiovascular risk reductions for sotagliflozin in adults with heart failure and type 2 diabetes, offering a possible platelet-based explanation for those protective effects. It also points toward possible future trials in chronic kidney disease and atrial fibrillation, though those remain hypotheses.
For people with type 2 diabetes, this research does not yet change treatment, since the findings come from mice and small blood-sample studies. Any future clinical use would depend on human trials confirming whether the platelet effect prevents cardiovascular events without increasing bleeding.
The takeaway
Sotagliflozin's effect on platelets is a promising lead, but readers should not expect changes to diabetes or heart care until human research confirms it.
Further reading
For related coverage, see Diabetes in Michigan health news.
Source note: This article includes information reported by SciTechDaily.
Live Poll
Would you trust a new drug that prevents blood clots if it raised bleeding risk?
